Markets:

Overview

News

Currencies

International

Treasuries

Collegium Pharmaceutical, Inc. - Common Stock (NQ:COLL)

33.78 -0.29 (-0.85%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Collegium Pharmaceutical, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

3 Growth Stocks We’re Skeptical Of

Today 0:31 EDT

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...

Via StockStory

Collegium Pharmaceutical’s Q1 Earnings Call: Our Top 5 Analyst Questions

May 14, 2026

Collegium Pharmaceutical’s first quarter was marked by solid execution and positive market reaction, supported by robust growth in its ADHD and pain manageme...

Via StockStory

Topics Earnings

Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know

May 13, 2026

What Happened? A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with servi...

Via StockStory

Topics Economy

Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics

May 12, 2026

From Collegium Pharmaceutical, Inc.

Via GlobeNewswire

Collegium Pharmaceutical (NASDAQ:COLL) Surges on Q1 Earnings Beat as JORNAY PM Revenue Jumps 36% ↗

May 07, 2026

Via Chartmill

Topics Earnings

Collegium Pharmaceutical Inc (NASDAQ:COLL) Priced for a Value Rebound ↗

May 05, 2026

Via Chartmill

Collegium Pharmaceutical Inc (NASDAQ:COLL) Presents a Compelling Value Investment Case ↗

March 28, 2026

Via Chartmill

1 Healthcare Stock with Competitive Advantages and 2 We Brush Off

May 11, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory de...

Via StockStory

COLL Q1 Deep Dive: ADHD Portfolio Expansion and Pain Segment Stability Drive Results

May 08, 2026

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) announced better-than-expected revenue in Q1 CY2026, with sales up 8.9% year on year to $193.5 ...

Via StockStory

Collegium (COLL) Q1 2026 Earnings Transcript ↗

May 07, 2026

Collegium (COLL) Q1 2026 Earnings Transcript

Via The Motley Fool

Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q1 CY2026 Expectations, Stock Soars

May 07, 2026

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 8.9% year o...

Via StockStory

Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress

May 07, 2026

From Collegium Pharmaceutical, Inc.

Via GlobeNewswire

Collegium Pharmaceutical (COLL) Q1 Earnings Report Preview: What To Look For

May 05, 2026

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be announcing earnings results this Thursday before market open. Here’s what investors sho...

Via StockStory

1 Small-Cap Stock on Our Watchlist and 2 We Question

May 04, 2026

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...

Via StockStory

3 Reasons to Sell COLL and 1 Stock to Buy Instead

April 29, 2026

Over the last six months, Collegium Pharmaceutical’s shares have sunk to $32.78, producing a disappointing 5.8% loss - a stark contrast to the S&P 500’s 4% g...

Via StockStory

Topics Stocks Supply Chain

Collegium to Report First Quarter 2026 Financial Results on May 7, 2026

April 23, 2026

From Collegium Pharmaceutical, Inc.

Via GlobeNewswire

3 of Wall Street’s Favorite Stocks with Questionable Fundamentals

April 14, 2026

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...

Via StockStory

3 Cash-Producing Stocks Walking a Fine Line

April 10, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...

Via StockStory

1 Value Stock on Our Buy List and 2 Facing Headwinds

April 06, 2026

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...

Via StockStory

Topics ETFs

GE HealthCare and Collegium Pharmaceutical Stocks Trade Down, What You Need To Know

April 02, 2026

What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa...

Via StockStory

Topics Economy Stocks World Trade

2 Profitable Stocks to Consider Right Now and 1 We Question

April 02, 2026

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

Via StockStory

Topics Bonds

Collegium's General Counsel Trims His Stake as the Company Doubles Down on ADHD ↗

March 30, 2026

This specialty pharma firm focused on pain management therapies reported a notable insider sale amid steady revenue and recent stock gains.

Via The Motley Fool

Topics Regulatory Compliance

Branded Pharmaceuticals Stocks Q4 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL)

March 25, 2026

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Collegium Pharmaceutical (NASDAQ:COLL) an...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Collegium Pharmaceutical EVP Sells Nearly 50,000 Shares Worth $2 Million ↗

March 25, 2026

Collegium Pharmaceutical, a leader in abuse-deterrent pain therapies, saw its Chief Commercial Officer trim his stake by more than 40%.

Via The Motley Fool

Topics Regulatory Compliance

Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory

March 19, 2026

From Collegium Pharmaceutical, Inc.

Via GlobeNewswire

BrightSpring Health Services, Collegium Pharmaceutical, and Phibro Animal Health Shares Are Soaring, What You Need To Know

March 16, 2026

What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. ...

Via StockStory

Topics Economy Stocks

3 Healthcare Stocks Walking a Fine Line

March 13, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have realiz...

Via StockStory

Collegium to Present New Real-World Data at PainConnect 2026

March 05, 2026

From Collegium Pharmaceutical, Inc.

Via GlobeNewswire

Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community

March 03, 2026

From Collegium Pharmaceutical, Inc.

Via GlobeNewswire

Collegium to Participate in Upcoming Investor Conferences

March 02, 2026

From Collegium Pharmaceutical, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.